A phase II trial of gemcitabine and mitoxantrone for patients with acute myeloid leukemia in first relapse

Clinical Lymphoma, Myeloma and Leukemia

Volumn 10, Issue 6, 2010, Pages 473-476

  Advani, Anjali S ^a   Shadman, Mazyar ^a   Ali Osman, Francis ^b   Barker, Andrew ^b   Rybicki, Lisa ^c   Kalaycio, Matt ^a   Sekeres, Mikkael A ^a   De Castro, Carlos M ^b   Diehl, Louis F ^b   Moore, Joseph O ^b   Beaven, Anne ^b   Copelan, Ed ^a   Sobecks, Ronald ^a   Talea, Parisa ^a   Rizzieri, David A ^b  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Multi drug resistance; Prognosis

Indexed keywords

ABCC4 PROTEIN; ABCC5 PROTEIN; GEMCITABINE; LRP PROTEIN; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; SLC28A1 PROTEIN; SLC28A2 PROTEIN; SLC29A1 PROTEIN; SLC29A2 PROTEIN; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BONE MARROW; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER REGRESSION; CANCER RELAPSE; CHROMOSOME ANALYSIS; CLINICAL ARTICLE; CONTINUOUS INFUSION; DIARRHEA; DRUG ERUPTION; DRUG FEVER; DRUG RESPONSE; DRUG WITHDRAWAL; FATIGUE; FEMALE; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFECTION; MALE; MUCOSA INFLAMMATION; NAUSEA; PAIN; PHASE 2 CLINICAL TRIAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 79952976406     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.3816/CLML.2010.n.082     Document Type: Article

References (17)

1. Rizzieri DA, Bass AJ, Rosner GL, et al. Phase I evaluation of prolonged-infusion gemcitabine with mitoxantrone for relapsed or refractory acute leukemia. J Clin Oncol 2002; 20:674-9. (Pubitemid 34111373)
2. Huang P, Chubb S, Hertel LW, et al. Action of 2'2'difluorodexoycytidine on DNA synthesis. Cancer Res 1991; 51:6110-7.
3. Braakhuis B, Ruiz Haperen V, Bovin E, et al. Schedule dependent anti-tumor effect of gemcitabine in in vitro model systems. Semin Oncol 1995; 22(suppl 11):42-6.
4. Hertel L, Botar G, Kroin JS, et al. Evaluation of the antitumor effect activity of gemcitabine (2'2'difluoro 2'2'deoxycytidine). Cancer Res 1990; 50:5517-722.
5. Rizzieri DA, Ibom VK, Moore JO, et al. Phase I evaluation of prolonged-infusion gemcitabine with fludarabine for relapsed or refractory acute myelogeneous leukemia. Clin Cancer Res 2003; 9:663-8. (Pubitemid 36182598)
6. Cheson BD, Bennet JM, Kopecky KJ, et al. International revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials. J Clin Oncol 2003; 21:4642-9. (Pubitemid 46594039)
7. Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002; 100:4325-36.
8. Larson RA, Sievers EL, Stadtmauer EA, et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer 2005; 104:1442-52. (Pubitemid 41356159)
9. Estey E, Kornblau S, Pierce S, et al. A stratification system for evaluating and selecting therapies in patients with relapsed or primary refractory acute myelogenous leukemia. Blood 1996; 88:756. (Pubitemid 26240412)
10. Keating MJ, Kantarjian H, Smith TL, et al. Response to salvage therapy and survival after relapse in acute myelogenous leukemia. J Clin Oncol 1989; 7:1071-80. (Pubitemid 19196530)
11. Tsimberidou AM, Paterakis G, Androutsos G, et al. Evaluation of the clinical relevance of the expression and function of P-glycoprotein, multidrug resistance protein, and lung resistance protein in patients with primary acute myelogenous leukemia. Leuk Res 2002; 26:143-54. (Pubitemid 34037851)
12. Kim DH, Lee NY, Baek JH, et al. Prognostic scoring model based on multi-drug resistance status and cytogenetics in adult patients with acute myeloid leukemia. Leuk Lymphoma 2006; 47:461-7. (Pubitemid 43102094)
13. Olesen LH, Norgaard JM, Pallisgaard N, et al. Validation and clinical implication of quantitative real-time PCR determination of MDR1 gene expression: Comparison with semi-quantitative PCR in 101 patients with acute myeloid leukemia. Eur J Haematol 2003; 70:296-303. (Pubitemid 36560527)
14. Sargent JM, Williamson C, Hall AG, et al. Evidence for the involvement of the glutathione pathway in drug resistance in AML. Adv Exp Med Biol 1999; 457:205-9. (Pubitemid 129735313)
15. Okcu MF, Selvan M, Wang LE, et al. Glutathione S-transferase polymorphisms and survival in primary malignant glioma. Clin Cancer Res 2004; 10:2618-25. (Pubitemid 38509134)
16. Ali-Osman F, Brunner JM, Kutluk TM, et al. Prognostic significance of glutathione S-transferase pi expression and subcellular localization in human gliomas. Clin Cancer Res 1997; 3:2253-61. (Pubitemid 28133143)
17. Tew KD. TLK-286: A novel glutathione S-transferase-activated prodrug. Expert Opin Investig Drugs 2005; 14:1047-54. (Pubitemid 41131655)